AOA Dx Demonstrates High Accuracy in AI-Powered Blood Test for Ovarian Cancer Detection in 1,000 Symptomatic Patient Samples
AOA Dx presented new data at the 2025 AACR Annual Meeting demonstrating high accuracy in early detection of ovarian cancer using its AI-powered multi-omic platform. In collaboration with CU Anschutz Ovarian Cancer Innovations Group (OCIG) and The University of Manchester, the platform achieved AUCs over 90% across approximately 1,000 real-world symptomatic patient samples, outperforming traditional biomarkers like CA125. These results highlight the potential of AOA Dx’s liquid biopsy to aid earlier, more accurate diagnosis and improve outcomes for women worldwide.